President, CEO & Chairman
Thomas Zindrick has served as chairman of Genelux Corporation since July 2021, and as president, CEO and a member of the board of directors since 2014. Thomas brings over 30 years of executive experience in life science and biotechnology to his role. Since 2018, he has served on the board, and currently serves as executive chair of Aeromics, a clinical-stage pharmaceutical company developing products for the treatment of ischemic stroke. Thomas previously served on the board of directors of Amitech Therapeutic Solutions from 2011 to February 2021 and DNX Biopharmaceuticals from November 2014 to March 2020. From 1993 to 2009, Thomas was at Amgen, where he held positions of increasing responsibility, including vice president associate general counsel and chief compliance officer. Prior to joining Amgen, Thomas was an attorney at The Dow Chemical Company. Thomas earned his J.D. from the University of Illinois College of Law and his B.A. in biology from North Central College in Naperville, Illinois.